TauC3 Biologics prepares for Series A to advance novel neurodegenerative disease treatment

The new funding also supports preparations for a planned £25m Series A round which is designed to initiate clinical development.

TBL-100 is designed to target tauC3, a harmful, altered form of the tau protein increasingly linked to the early stages of frontotemporal dementia, progressive supranuclear palsy and Alzheimer’s disease.

TauC3 disrupts essential processes inside neurons and contributes to the formation of toxic protein complexes thought to drive disease progression.

By selectively recognising this pathogenic form of tau, TBL-100 aims to remove toxic tauC3-containing proteins both inside and outside brain cells. This approach is intended to support healthier neuronal function, reduce inflammation and slow the spread of tau-driven pathology.

Daniel Chain, CEO of TauC3 Biologics, said: “Targeting tauC3 allows us to act directly on the toxic species that drives disease progression - addressing a fundamental limitation behind earlier failures in tauopathy drug development. 

“With this investment, we are well positioned to further advance TBL-100 toward clinical development, where we aim to translate our mechanistic insights into a therapy that could meaningfully alter outcomes for individuals affected by these devastating, fatal neurodegenerative disorders.”

The company plans to begin clinical development in frontotemporal dementia caused by tau pathology, with future expansion into PSP and Alzheimer’s disease. Work also continues on establishing tauC3 as a biomarker to support earlier and more precise diagnosis.